Logo

APM

Aptorum Group Limited

APM

Aptorum Group Limited • NASDAQ
$1.35 ▲ 0.75% (+0.01)
Market Cap $9.64 M
52w High $7.49
52w Low $0.65
Dividend Yield 0%
P/E -3.97
Volume 19.70K
Outstanding Shares 7.14M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $0 $928K ▼ $-1.624M ▲ 0% $-0.29 ▲ $-1.42M ▲
Q2-2024 $0 $2.469M ▼ $-2.644M ▼ 0% $-0.5 ▼ $-2.335M ▼
Q4-2023 $0 ▼ $3.535M ▼ $2.662M ▲ 0% ▲ $0.51 ▲ $2.741M ▲
Q2-2023 $431.378K ▼ $5.874M ▼ $-5.487M ▲ -1.272K% ▼ $-1.43 ▲ $-5.841M ▲
Q4-2022 $768.427K $8.515M $-7.914M -1.03K% $-2.22 $-8.167M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $874.238K ▲ $16.13M ▼ $4.353M ▼ $21.135M ▼
Q2-2024 $783.085K ▼ $17.705M ▼ $4.528M ▼ $22.655M ▼
Q4-2023 $2.005M ▲ $20.64M ▲ $5.257M ▲ $24.846M ▲
Q2-2023 $340.306K ▼ $14.412M ▼ $1.633M ▼ $21.844M ▲
Q4-2022 $1.985M $20.867M $13.034M $15.712M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-1.624M ▲ $89.728K ▲ $0 ▼ $1.425K ▲ $91.153K ▲ $89.73K ▲
Q2-2024 $-2.644M ▼ $-1.281M ▲ $58.621K ▼ $0 ▼ $-1.222M ▼ $-1.281M ▲
Q4-2023 $2.662M ▲ $-1.537M ▲ $65.986K ▼ $3.006M ▲ $1.535M ▲ $-1.537M ▲
Q2-2023 $-5.487M ▲ $-6.242M ▼ $558.781K ▲ $1.141M ▼ $-4.542M ▼ $-6.245M ▼
Q4-2022 $-7.914M $-5.463M $-266.564K $3.546M $-2.183M $-5.499M

Five-Year Company Overview

Income Statement

Income Statement Aptorum is essentially a pre‑revenue company: there is no meaningful recurring sales yet, so the income statement is driven almost entirely by research, development, and overhead costs. The business has been loss‑making throughout the past several years, which is typical for a small, clinical‑stage biotech and diagnostics company. Reported earnings per share have swung sharply from year to year, reflecting one‑off items and capital structure changes (such as reverse splits) more than any underlying business momentum. Overall, the pattern is consistent with an early‑stage company still in the investment phase rather than one generating stable profits.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and equity and limited cash resources. On the positive side, there is little to no financial debt, so the company is not heavily burdened by interest obligations. However, the small size of the asset base and modest cash levels underline that this is a thinly capitalized business that depends on continued access to external funding. Financial flexibility is limited, and the balance sheet does not provide a large cushion against setbacks or delays in development and commercialization.

Cash Flow

Cash Flow Cash flows from operations have been consistently negative, reflecting ongoing spending on research, clinical work, and corporate overhead without offsetting product revenue. There is essentially no meaningful investment in fixed assets, so free cash flow is negative for the same reason: operating cash burn. This means the company’s ability to continue funding its pipeline and the DiamiR integration will rely on raising capital through equity, partnerships, grants, or other external sources. The core cash flow risk is that scientific and commercial timelines may stretch longer than the available funding runway.

Competitive Edge

Competitive Edge Aptorum’s competitive position is built around a niche focus rather than scale. The planned merger with DiamiR pushes the company toward precision diagnostics for neurodegenerative diseases, where blood‑based tests for brain health are an emerging and still relatively under‑served area. Key strengths include a CLIA‑certified, accredited lab in the U.S., a sizable patent portfolio around microRNA diagnostics, and a history of working on high‑unmet‑need indications such as neurodegeneration, rare pediatric cancers, and infectious diseases. Against this, Aptorum is a very small player operating in markets dominated by much larger diagnostics and pharmaceutical companies with deeper resources, established commercial networks, and larger R&D budgets. Execution, partnering, and clear clinical differentiation will be critical for maintaining any edge.

Innovation and R&D

Innovation and R&D Innovation is the core asset here. Aptorum combines several platforms: a computational drug‑repurposing engine (Smart‑ACT), a microbiome‑based therapeutics effort, rapid pathogen detection technology (RPIDD), and, via DiamiR, a microRNA blood‑based diagnostic platform for brain disorders. This mix gives the company multiple “shots on goal” across both therapeutics and diagnostics and supports a theranostics vision where tests and treatments inform each other. The IP base and the CLIA‑certified lab strengthen the innovation story. The main constraints are scale and funding: advancing multiple platforms and clinical programs at once is costly, so prioritization and focus will be essential. The real test will be turning these technologies into validated products with clear clinical and commercial use cases.

Summary

Aptorum is in the middle of a strategic pivot from being primarily a small, clinical‑stage drug developer to becoming a precision diagnostics and theranostics company, anchored by the DiamiR merger. Financially, it remains very early stage: no meaningful revenues, ongoing losses, negative cash flow, and a thin but largely debt‑free balance sheet. The investment case around the business rests on its technology platforms, intellectual property, and regulatory assets (like the CLIA lab), not on current financial performance. If the company can successfully commercialize its neurodegenerative diagnostics, secure partnerships, and selectively advance its therapeutic programs, its profile could change meaningfully. At the same time, funding dependence, competitive pressure from much larger peers, and clinical and regulatory uncertainty make the outlook highly sensitive to execution and timing.

NEWS

November 19, 2025 · 8:00 AM UTC

DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

Read more

October 10, 2025 · 9:54 AM UTC

Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

Read more

October 9, 2025 · 8:55 AM UTC

As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

Read more

September 5, 2025 · 8:00 AM UTC

Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Read more